Compatibility of Melphalan in Iodinated Contrast Media
Author(s): Shi Zhanquan, Abruzzo Todd, Wanasathop Apipa, Li S Kevin
Issue: Jan/Feb 2020 - Volume 24, Number 1
View All Articles in Issue
Page(s): 83-85
Download in electronic PDF format for $75
Abstract: Melphalan is used in selective ophthalmic artery infusion chemotherapy. In the procedure to catheterize the ophthalmic artery in selective ophthalmic artery infusion chemotherapy, the microcatheter is usually filled with an iodinated contrast medium. It is not known whether mixing of iodinated contrast medium with melphalan solutions promotes precipitation of melphalan during selective ophthalmic artery infusion chemotherapy. The objective of the present study was to examine the compatibility of melphalan and iodinated contrast medium. In the experiments, melphalan solutions were prepared with and without iodinated contrast medium (iohexol 300 mg Iodine/mL or ioversol 74%). Melphalan solution of clinically relevant concentration (0.45 mg/mL) in the absence of iodinated contrast medium was evaluated as a reference. The 0.45-mg/mL melphalan solution was diluted with iodinated contrast medium at 1:9 and 1:1 ratios to form solutions comprising iodinated contrast medium at 10% or 50% (v/v), and each was evaluated. The formation of particles was examined using filtration (pore size 0.45 µm) followed by high-performance liquid chromatography at four quarterly time intervals (15 min, 30 min, 45 min, and 60 min) over a 1-hour period after solution preparation. High-performance liquid chromatography analysis of microfiltered solutions did not reveal evidence of melphalan crystal formation over a 60-minute period for the solutions studied. The filtration studies suggest that mixing of the iodinated contrast medium with melphalan solutions does not result in significant melphalan precipitation.
Related Keywords:
melphalan, iodinated contrast media, selective ophthalmic artery infusion chemotherapy, SOAIC, intraocular retinoblastoma, compatibility
Related Categories:
CANCER AND AIDS, NUCLEAR, OPHTHALMICS, PEER-REVIEWED, STABILITIES, COMPATIBILITIES
Printer-Friendly Version
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Compatibility of Melphalan in Iodinated Contrast Media
Shi Zhanquan, Abruzzo Todd, Wanasathop Apipa, Li S Kevin
|
Jan/Feb 2020
Pg. 83-85
|
Basics of Compounding for the Treatment of Warts
Allen Loyd V Jr
|
Mar/Apr 2004
Pg. 126-129
|
N-acetylcysteine Used to Decrease the Incidence of Contrast-Induced Nephropathy Following Radiographic Procedures: A Literature Review
McElhiney Linda F
|
Mar/Apr 2005
Pg. 99-103
|
Stability and Compatibility of Reconstituted Caspofungin in Select Elastomeric Infusion Device
Tsiouris Maria, Ulmer Marisa, Yurcho James F, Hooper Kevin L, Gui Min
|
Sep/Oct 2010
Pg. 436-439
|
Compatibility and Stability of Palonosetron Hydrochloride with Four Neuromuscular Blocking Agents During Simulated Y-Site Administration
Trusley Craig, Ben Michel, Kupiec Thomas C, Trissel Lawrence A
|
Mar/Apr 2008
Pg. 156-160
|
Compatibility and Stability of Palonosetron Hydrochloride with Gentamicin, Metronidazole, or Vancomycin During Simulated Y-Site Administration
Kupiec Thomas C, Ben Michel, Trusley Craig, Trissel Lawrence A
|
Mar/Apr 2008
Pg. 170-173
|
Compatibility and Stability of Palonosetron Hydrochloride and Propofol During Simulated Y-Site Administration
Trissel Lawrence A, Trusley Craig, Kupiec Thomas C, Ben Michel
|
Jan/Feb 2009
Pg. 78-80
|
Medium-Chain Triglycerides Oral Vehicle, Anhydrous
Allen Loyd V Jr
|
Jan/Feb 2006
Pg. 63
|
Anhydrous Medium-chain Triglycerides Gel
Allen Loyd V Jr
|
Jul/Aug 2018
Pg. 316
|
Intravenous Physical Compatibility of Heparin Sodium and Furosemide
Maktabi Briana, Howard Mitchell S, Baki Gabriella, Churchwell Mariann D
|
Nov/Dec 2022
Pg. 522-526
|
Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures
Foushee Jaime A, Meredith Pmichaele, Fox Laura M, Grace EdwardE
|
Jul/Aug 2016
Pg. 328-332
|
Physicochemical Stability and Compatibility of Revefenacin (LAMA) and Formoterol Fumarate (LABA) Inhalation Solution Admixture
Ngim Kenley, Patel Jalpa
|
May/Jun 2020
Pg. 242-245
|
Compatibility Screening of Bivalirudin During Simulated Y-Site Administration with Other Drugs
Trissel Lawrence A, Saenz Christopher
|
Jul/Aug 2002
Pg. 311-315
|
Acetylcysteine 200-mg/mL Oral Liquid
Allen Loyd V Jr
|
Sep/Oct 2007
Pg. 417
|
Acetylcysteine 200-mg Packets
Allen Loyd V Jr
|
Sep/Oct 2007
Pg. 418
|
Palonosetron Hydrochloride Compatibility and Stability with Three Beta-Lactam Antibiotics During Simulated Y-Site Administration
Ben Michel, Trusley Craig, Kupiec Thomas C, Trissel Lawrence A
|
Nov/Dec 2007
Pg. 520-524
|
Compatibility of Caspofungin Acetate Injection with Other Drugs During Simulated Y-Site Coadministration
Chan Pak, Heatherly Kathy, Kupiec Thomas C, Trissel Lawrence A
|
May/Jun 2008
Pg. 276-278
|
Physical Compatibility of Medications Used in Critically Ill Patients with Balanced Fluid Solutions
Wilder Alyson G, Foushee Jaime A, Fox Laura M, Navalle Jordan, Wright Adrienne M, Greer Megan A
|
May/Jun 2020
Pg. 238-241
|
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate
Wu George, Yeung Stanley, Chen Frank
|
Jan/Feb 2017
Pg. 66-75
|
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride
Wu George, Yeung Stanley, Chen Frank
|
Jan/Feb 2017
Pg. 76-82
|
Return to Top |